is the time ripe for investment?

According to GlobalData, investment in the Asia-Pacific (APAC)
biotech sector is lagging behind its US rivals. Over the period
2018 to 2022, the APAC region received £23 billion ($29 billion)
for the development of innovative early-stage drugs, whereas
American biotech received $72 billion; both regions have seen a
decline in investment activity during 2022, largely due to
inflation and geopolitical issues (Figure 1).

Figure 1: Early-stage venture…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source